World Lung 2025 preview – best of the rest
Posters and mini-orals include another VEGF bispecific.
Gilead gets into in vivo Car-T
Interius, one of the most advanced players, will cost $350m.
Astellas and Amgen join the pan-KRAS push
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
Otsuka zips into adjuvant use
As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
World Lung 2025 preview – late-breakers in focus
Summit and Nuvalent have scored prized plenary spots.
Pfizer’s Global Blood buy fails to Thrive
Inclacumab fails, and osivelotor is on hold.
CatalYm joins Pfizer in pivotal cachexia push
Shortly after ponsegromab, visugromab is to start phase 2/3.
More conjugates pile into the clinic
J&J, Astra, Pfizer and others move yet more ADCs into human studies.
Compass makes hay in bispecifics
Progress with three bispecific molecules is rewarded with a $120m equity raise.
Novita goes into phase 3
Meanwhile, ASK Pharm challenges Hutchmed in cMet.
